Hepatic peroxisome proliferator-activated receptor \(\gamma\) and \(\alpha\)-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity

Nathan J. Shores, Maria Cássia Mendes-Corrêa, Ivana Maida, JoLyn Turner, Kevin P. High, Sergio Babudieri, Marina Núñez

1Wake Forest University Health Sciences, Department of Internal Medicine, Section on Infectious Diseases, Medical Center Boulevard, Winston Salem, NC, United States. 2Faculdade de Medicina do ABC, Unidade de Referência em Doenças Infecciosas, Santo André/SP, Brazil. 3Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Moléstias Infecciosas e Parasitárias, São Paulo/SP, Brazil. 4Università degli Studi Sassari, Istituto Malattie Infettive e Parassitarie, Sassari/SS, Italy. 5Charleston Gastroenterology Spec, Charleston/SC, United States.

OBJECTIVE: To determine peroxisome proliferator activated receptor \(\alpha\) and \(\gamma\) mRNA expression in liver tissue of hepatitis C virus-infected patients with and without human immunodeficiency virus and its possible contribution to an acceleration of liver disease progression.

METHODS: We measured peroxisome proliferator-activated receptor \(\alpha\) and \(\gamma\) mRNA expression by real-time polymerase chain reaction in liver tissues from 40 subjects infected only with hepatitis C virus, 36 subjects co-infected with hepatitis C virus and human immunodeficiency virus and 11 normal adults.

RESULTS: Hepatic mRNA expression of both peroxisome proliferator-activated receptors was significantly lower in hepatitis C virus-infected subjects with and without human immunodeficiency virus co-infection compared to the controls. Non-black race was also identified as a predictor of lower peroxisome receptor \(\alpha\) and \(\gamma\) mRNA expression. Compared to subjects infected only with hepatitis C virus, liver peroxisome receptor \(\gamma\) mRNA expression was significantly lower in hepatitis C virus/human immunodeficiency virus co-infected subjects (0.0092 in hepatitis C virus/human immunodeficiency virus-co-infected subjects vs. 0.0120 in hepatitis C virus-only; \(p=0.004\)). Hepatic peroxisome receptor \(\alpha\) mRNA expression in the hepatitis C virus-infected patients was lower in the presence of human immunodeficiency virus co-infection in non-black subjects (0.0769 vs. 0.1061; \(p=0.02\)), whereas the levels did not vary based on human immunodeficiency virus status among black subjects.

CONCLUSION: mRNA expression of both peroxisome proliferator-activated receptors is impaired in hepatitis C virus-infected liver and further reduced by human immunodeficiency virus co-infection, although the suppressive effects of the viruses are substantially mitigated in black patients.

KEYWORDS: Nuclear Receptors; PPAR; Hepatitis C; HIV Infection; mRNA Expression; Liver Tissue.

Shores NL, Mendes-Correa MC, Maida I, Turner J, High KP, Babudieri S, et al. Hepatic peroxisome proliferator-activated receptor \(\gamma\) and \(\alpha\)-mRNA expression in HCV-infected adults is decreased by HIV co-infection and also affected by ethnicity. Clinics. 2015;70(12):790-796

Received for publication on August 23, 2015; First review completed on September 18, 2015; Accepted for publication on October 20, 2015

E-mail: cassiamc@uol.com.br

*Corresponding author

INTRODUCTION

Chronic hepatitis C virus (HCV) infection in the setting of human immunodeficiency virus (HIV) co-infection is characterized by accelerated liver disease, although the underlying reasons are unclear (1). Activation of peroxisome proliferator-activated receptor (PPAR) \(\alpha\) and \(\gamma\), members of the nuclear receptor superfamily, inhibits the expression of inflammatory cytokines and chemokines and reduces hepatic inflammatory processes (2). Additionally, PPAR\(\gamma\) activation maintains a quiescent hepatic stellate cell phenotype and decreases pro-fibrogenic products (2). The HCV core protein reduces the expression of hepatic PPAR\(\alpha\) in HCV mono-infected patients (3). The role of PPAR\(\gamma\) in the pathogenesis of HCV-related liver disease is less clear because the data are conflicting (2-5). Decreased expression of PPAR\(\gamma\) mRNA has been reported in liver biopsies of HIV-infected subjects with insulin resistance and unexplained liver enzyme elevation (6), suggesting an effect of HIV on liver PPAR\(\gamma\) expression.

Copyright © 2015 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

No potential conflict of interest was reported.

DOI: 10.6061/clinics/2015(12)05
This result is supported by several in vitro and in vivo studies that reported evidence for HIV infection of the liver (7).

We hypothesized that HIV infection reduces the expression of PPARα in the HCV-infected liver. We also hypothesized that reduced PPARα and PPARγ expression would accelerate the process of liver fibrosis in patients with HIV/HCV co-infection.

■ METHODS

We conducted a multicenter, comparative, cross-sectional study that included liver tissue samples from HCV-only infected, HCV/HIV-co-infected and HCV/HIV-uninfected control subjects. The local institutional review boards (IRB) approved the research project. Informed consent was obtained from each patient included in the study and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in an a priori approval by the institution’s human research committee. The participating centers were Wake Forest University Health Sciences, Winston Salem, NC, USA, Unidade de Referência em Doenças Hepáticas, Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, and Istituto Malattie Infettive, University of Sassari, Sassari, Italy.

Selection of subjects

Subjects chronically infected with HCV, with or without concurrent HIV co-infection, who were 18 years of age or older were eligible for the study. Active HCV or HIV infection was defined as detectable plasma HCV RNA or a positive anti-HIV antibody titer at the time of enrollment, respectively. Subjects were excluded if other causes of liver disease were present, including hepatitis B virus (HBV) co-infection (HBsAg positive), hemochromatosis, autoimmune hepatitis, Wilson’s disease, or alpha-antitrypsin deficiency. Alcohol intake was not an exclusion criterion, but the amount consumed was specified as accurately as possible based on patient reports. Liver samples from 11 HIV- and HCV-uninfected control subjects that were previously collected as part of another IRB-approved study at Wake Forest University Health Sciences were used for comparative analysis. At the time of collection, the control subjects had screened negative for other known liver diseases. However, no clinical or demographic data were available for these subjects.

Data collection

Data were collected from medical records and included age, sex, weight, body mass index (BMI; kg/m²), race, country of origin, HCV genotype, serum HCV RNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, liver biopsy data (fibrosis, inflammation, and steatosis), absolute and % CD4 + lymphocytes, HIV RNA serum levels, highly active antiretroviral therapy (HAART) at the time of liver biopsy, diabetes mellitus (DM) status, alcohol intake, and serum cholesterol and triglyceride levels. Data from liver biopsies included METAVIR scores for fibrosis (F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = portal fibrosis with few septa, F3 = numerous septa without cirrhosis, and F4 = cirrhosis), inflammation (‘activity score’ of A0 = no activity, A1 = mild activity, A2 = moderate activity, and A3 = severe activity), and steatosis scored as used in non-alcoholic fatty liver disease (<5%, none, 5-33%, mild, 34-66%, moderate, and >66%, severe).

Tissue Preparation

All HCV-infected or HCV/HIV-co-infected subjects underwent liver biopsies as part of the routine medical care for their liver disease according to local practices. A portion of each biopsy was stored immediately in RNA stabilizing solution (RNAlater, Ambion, Austin, TX, USA) according to the package insert. Total RNA was extracted from the liver biopsies using RNA STAT-60 Reagent (Tel-Test, Friendswood, TX, USA) according to the manufacturer’s protocol. Briefly, liver tissues were homogenized in RNA STAT-60. Then, chloroform was added and the samples were centrifuged to separate the homogenate into two phases. The upper aqueous phase was transferred to a nuclease-free tube and mixed with isopropanol, and the RNA was precipitated overnight at -20°C. After centrifugation, the RNA pellet was washed with 75% ethanol, briefly air dried and re-suspended in nuclease-free water. The quality of the RNA was confirmed using the Agilent Bioanalyzer system.

Quantification of PPARα and PPARγ mRNA expression by RT-PCR

Two micrograms of RNA was reverse-transcribed to cDNA using the Applied Biosystems High Capacity RNA to cDNA Kit (Applied Biosystems, Foster City, CA, USA). PPARα, PPARγ, and GAPDH expression was assessed by real-time PCR (RT-PCR) using pre-formulated TaqMan Gene Expression Assays for each gene (Applied Biosystems, Foster City, CA, USA) composed of two unlabeled primers and a FAM dye-labeled MGB probe designed to span introns and avoid the amplification of genomic DNA. The RT-PCR results were calculated using the comparative Ct method based on relative gene expression compared to GAPDH.

Statistical methods

The primary outcome of the study was the analysis of comparative mRNA expression of PPARα and PPARγ in the livers of HCV-only versus HCV/HIV-co-infected subjects. Based on a previous report in HCV-infected subjects in which the mean PPARα level was 1.8 and the standard deviation was 2.8 (7), 39 individuals were needed in each group to rule out equivalence of the means (HCV and HCV/HIV groups) and to obtain a desired power of 80% and two-sided significance level of 5%. Eleven samples from subjects negative for viral hepatitis were included for comparison (control group).

The results are presented in absolute numbers for continuous variables and in proportions for categorical variables. Comparisons between groups were performed using Fisher’s exact test for categorical variables and the t or ANOVA test for continuous variables. Univariate and multivariate linear regression analyses were performed to identify independent outcome predictor factors of PPARα and PPARγ. All p-values <0.05 were considered statistically significant. Statistical Package for the Social Sciences (SPSS), version 20.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis.

■ RESULTS

We were able to obtain adequate liver samples for the study from 40 HCV-only infected and 36 HCV/HIV-co-infected subjects. The characteristics of the subjects are summarized in Table 1. Demographics were similar between the two groups with the exception of race and country of origin. There were more white subjects in the HCV-only infected group. Serum HCV RNA levels were higher and ALT levels were lower in the HCV/HIV-co-infected group,
whereas the inflammation and fibrosis METAVIR scores were comparable. The HCV/HIV-co-infected subjects had significantly higher triglyceride levels compared to the HCV-only infected subjects. All HIV-infected subjects had CD4 counts $>$ 200 cells/mm$^3$ and 98% were receiving HAART.

### Quantification of PPAR$\alpha$ mRNA expression by RT-PCR

Based on RT-PCR analyses of liver samples, controls had higher PPAR$\alpha$ mRNA expression levels compared to both the HCV-only ($p=0.001$) and HCV/HIV-co-infected subjects ($p=0.0001$) (Figure 1A). The expression levels were comparable between the HCV-only and HCV/HIV-co-infected subjects (0.1178 vs. 0.0931; $p=0.1$). In both HCV-infected groups, the PPAR$\alpha$ levels were higher among subjects from the United States (US) compared to non-US subjects ($p=0.02$). There were also differences in PPAR$\alpha$ mRNA expression based on race, with black subjects having a significantly higher expression level compared to non-black subjects (0.1381 vs. 0.0946; $p=0.02$). Given these racial differences, additional analyses were performed to compare HCV-only infected and HCV/HIV-co-infected subjects stratified by race. A significantly lower level of PPAR$\alpha$ mRNA expression

### Table 1 - Characteristics of the patients according to HIV status*.

|                      | HCV-Only | HCV & HIV | $p$-value |
|----------------------|----------|-----------|-----------|
| N                    | 40       | 36        | ---       |
| Age                  | 47 (28-69) | 49 (36-68) | 0.4       |
| Male sex             | 29 (72.5) | 24 (67)   | 0.4       |
| Weight               | 82 (53-130) | 75 (51-121) | 0.2       |
| BMI                  | 28 (18-36) | 26 (17-37) | 0.3       |
| Race                 | ---      | ---       | 0.003     |
| White                | 29 (72.5) | 12 (33)   | <0.0001   |
| Black                | 6 (15)   | 14 (39)   | 0.2       |
| Mixed/Hispanic       | 4 (10)   | 10 (28)   | 0.1       |
| Native American      | 1 (2.5)  | 0         | 0.003     |
| Country              | ---      | ---       | 0.003     |
| Brazil               | 9 (22.5) | 21 (58)   | 0.2       |
| Italy                | 12 (30)  | 0         | 0.003     |
| USA                  | 19 (47.5)| 15 (42)   | 0.1       |
| HCV genotype         | ---      | ---       | 0.5       |
| 1                    | 34 (94)  | 30 (91)   | 0.001     |
| 2                    | 0        | 1 (3)     | 0.02      |
| 3                    | 1 (3)    | 2 (6)     | 0.02      |
| 4                    | 1 (3)    | 0         | 0.02      |
| HCV RNA, log$_{10}$  | 5.82 (3.16-7.00) | 6.17 (5.1-7.59) | 0.04     |
| ALT                  | 100 (15-351) | 62 (15-213) | 0.02     |
| AST                  | 93 (20-1,018) | 47 (16-103) | 0.1      |
| METAVIR fibrosis score| ---      | ---       | 0.6       |
| F0                   | 4 (10)   | 6 (17)    | 0.005     |
| F1                   | 14 (35)  | 14 (35)   | 0.005     |
| F2                   | 14 (35)  | 13 (36)   | 0.005     |
| F3                   | 5 (12.5) | 2 (5)     | 0.005     |
| F4                   | 3 (7.5)  | 1 (3)     | 0.005     |
| METAVIR inflammation score | ---      | ---       | 0.3       |
| A0                   | 1 (2.5)  | 5 (14)    | 0.005     |
| A1                   | 17 (42.5)| 15 (42)   | 0.005     |
| A2                   | 17 (42.5)| 11 (30)   | 0.005     |
| A3                   | 5 (12.5) | 5 (14)    | 0.005     |
| Steatosis            | ---      | ---       | 0.4       |
| Unknown              | 9 (22.5) | 7 (19.5)  | 0.005     |
| None                 | 18 (45)  | 19 (53)   | 0.005     |
| Mild                 | 6 (15)   | 8 (22)    | 0.005     |
| Moderate             | 4 (10)   | 1 (3)     | 0.005     |
| Severe               | 3 (7.5)  | 1 (3)     | 0.005     |
| CD4                  | ---      | 540 (260-1049) | 0.005    |
| CD4%                 | ---      | 27 (15-44) | 0.005    |
| HIV RNA              | ---      | 177 (<50-1450) | 0.005   |
| HAART                | ---      | ---       | 0.005     |
| No                   | ---      | 3 (8)     | ---       |
| AZT                  | ---      | 11 (68)   | ---       |
| Dideoxynucleosides   | ---      | 2 (6)     | ---       |
| PI                   | ---      | 20 (59)   | ---       |
| DM                   | ---      | 6 (17)    | 0.005     |
| Current alcohol use  | ---      | 9 (26)    | 0.005     |
| Cholesterol levels   | 169 (113-231) | 159 (91-226) | 0.005    |
| Triglyceride levels  | 83 (37-2091) | 149 (55-428) | 0.005    |

* Mean (range) unless otherwise stated.

BMI: body mass index; HCV: hepatitis C virus; HIV: human immunodeficiency virus; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes mellitus.
was found among non-black subjects in the HCV/HIV-co-infected group compared to the HCV-only group (0.0769 vs. 0.1061; \( p = 0.02 \)) (Figure 1B), whereas there were no differences among black subjects (\( p = 0.2 \)) (Figure 1C). Other factors that were evaluated and found to have no association with PPAR\(_a\) gene expression included age, sex, BMI, HCV genotype, HCV RNA serum levels, DM, alcohol use, CD4 counts, serum HIV RNA levels and HAART therapy. In a multivariate linear regression model in which HIV status, black race, and country of origin were included, all three factors lost statistical significance. The pathology results demonstrated that moderate-to-severe inflammation was associated with lower PPAR\(_a\) mRNA expression among non-black, non-HIV subjects (0.0868 in METAVIR A2/A3 subjects vs. 0.1255 in A0/A1 subjects; \( p = 0.01 \)), but no associations were detected in the remaining groups.

### Quantification of PPAR\(_\gamma\) mRNA expression by RT-PCR

RT-PCR analysis of PPAR\(_\gamma\) mRNA in the liver samples indicate that the controls had a higher level of expression compared to both the HCV-only infected (\( p = 0.01 \)) and HCV/HIV-co-infected subjects (\( p = 0.001 \)) (Figure 2A). The expression levels were significantly higher in the HCV-only-infected subjects compared to the HCV-HIV-co-infected subjects (0.0120 vs. 0.0092; \( p = 0.004 \)). In both HCV-infected groups, PPAR\(_\gamma\) levels were higher among US subjects compared to non-US subjects (\( p = 0.04 \)). There were also differences in PPAR\(_\gamma\) expression based on race, with black subjects having a significantly higher expression level compared to non-black subjects (0.0101 vs. 0.0125; \( p = 0.03 \)). However, there was a significantly lower level of PPAR\(_\gamma\) mRNA expression in HCV-HIV-co-infected subjects compared to HCV-only subjects in both groups [non-black (\( p = 0.001 \)) (Figure 2B) and black subjects (\( p = 0.03 \))] (Figure 2C). Other factors evaluated and found to have no association with PPAR\(_\gamma\) gene expression include age, sex, BMI, HCV genotype, HCV RNA serum levels, DM, alcohol use, CD4 counts, serum HIV RNA levels and HAART therapy (Table 2). In multivariate linear regression analyses, only HIV-co-infection (\( p = 0.001 \)) and non-black race (\( p = 0.04 \)) were independently associated with lower PPAR\(_\gamma\) expression (Table 2). The pathology findings demonstrated that more advanced fibrosis in liver biopsy was associated with lower hepatic PPAR\(_\gamma\) mRNA expression among non-black, non-HIV subjects (METAVIR score F2/F3/F4 0.0102 vs. METAVIR score F0/F1 0.0126; \( p = 0.04 \)). There was no association between PPAR\(_\gamma\) mRNA expression and steatosis in any group.

### DISCUSSION

Our results show that hepatic PPAR\(_a\) and PPAR\(_\gamma\) mRNA expression levels were reduced in the presence of HCV infection. Surprisingly, we observed marked differences by ethnicity; as a result, the power of the study to detect differences based on HIV status was diminished to a large extent, especially with regard to PPAR\(_a\). To the best of our
knowledge, this is the first report to examine or identify differences in PPAR\(\alpha\) and PPAR\(\gamma\) liver expression by race. Our results suggest that genetic polymorphisms linked to ethnicity may explain this finding. Notably, PPAR has been implicated in the pathogenesis of hepatic steatosis, which has been reported to be less frequent among black subjects (8-10). Nevertheless, the non-black group is very heterogeneous because it includes Caucasians and mixed ethnicities, especially among subjects from Brazil. Because the liver samples were obtained from diverse races and different countries, we could not exclude the possibility that nutritional or other environmental factors might have had an effect on liver PPAR\(\alpha\) and/or PPAR\(\gamma\) expression.

In line with previous reports, PPAR\(\alpha\) gene expression was impaired in the livers of HCV-infected subjects (3,4,11,12). Our data indicate that HIV infection also decreased PPAR\(\alpha\) gene expression, as revealed in non-black subjects. However, the effect of HIV was mitigated in black patients, suggesting that this group might be less vulnerable to the effects of the HIV virus on PPAR\(\alpha\) expression.

PPAR\(\alpha\) plays a pivotal anti-inflammatory role in hepatocytes (2,13). More severe liver inflammation in HCV-infected subjects with reduced PPAR\(\alpha\) expression in hepatocytes has been reported by some but not all authors (3,4,12). In our study, an inverse correlation between PPAR\(\alpha\) expression and necroinflammatory activity was only observed in the non-black HCV-only infected group based on METAVIR scores, a method that is likely inadequate for the detection of subtle trends in HIV-related fibrosis in HCV-infected patients. Larger studies with a more homogeneous population using a more precise method of inflammation measurement might shed additional light on this subject.

In contrast with prior reports, PPAR\(\gamma\) gene expression was reduced in the livers of HCV-infected subjects compared to the controls (3,12). PPAR\(\gamma\) expression in HCV-infected livers was further reduced by HIV co-infection. PPAR\(\gamma\) is primarily expressed in hepatic stellate cells and its expression disappears when these cells undergo myofibroblastic differentiation and fibrogenesis (14). There appears to be a critical role for PPAR\(\gamma\) in liver fibrogenesis, and treatment of hepatic stellate cells with synthetic PPAR\(\gamma\) suppresses the fibrogenetic process (2,5). In our study, an inverse correlation was observed between PPAR\(\gamma\) expression and more advanced fibrosis in the non-black HCV-only-infected group. The limitations of the present study can be overcome by measuring liver fibrosis using other methods, such as morphometric image analysis or quantification of fibrosis proteins and using a larger, more homogeneous population (9,15).

Our findings suggest that genetic polymorphisms may determine the expression of PPAR\(\alpha\) and PPAR\(\gamma\) in the liver and that the impairment induced by the HCV and HIV viruses is mitigated in subjects of black ethnicity. Genetic studies are needed to determine why hepatic expression of these nuclear

Figure 2 - Quantification of liver peroxisome proliferator-activated receptor \(\gamma\) mRNA expression by RT-PCR. (A) All patients: control (n=11), hepatitis C virus (n=40), and hepatitis C virus-HIV subjects (n=36) (error bars represent standard deviations). (B) Only non-black subjects: hepatitis C virus and hepatitis C virus-HIV subjects (p=0.001). (C) Only black subjects: hepatitis C virus and hepatitis C virus-HIV subjects (p=0.03).
receptors differs by race. Despite the complexity introduced by race, PPARα and PPARγ hepatic expression were affected by HIV infection. PPARα expression is most robust in hepatocytes, although it is also expressed in other cell types. Hepatocytes have not been demonstrated to be infected by HIV, although HIV-1 has been proposed to be present in the liver and can promote fibrosis, most likely through indirect effects on hepatocytes (7,16). There is evidence from studies using cell lines that HIV may infect human stellate cells (17). The reduction in PPARγ expression, which is more abundant in stellate cells, might be due to direct infection by HIV. HIV may also affect PPARα and PPARγ expression via immune activation and the disruption of cellular functions. Despite some limitations of our study, including lack of adequate samples to test protein expression, small sample size, ethnic and HCV genotype diversity of the subjects, and lack of a more refined measurement of liver inflammation and fibrosis, several findings are intriguing and deserve further attention. Additional studies are needed to elucidate the mechanisms underlying the decreased hepatic PPARα and PPARγ mRNA expression observed in our study. Thus, larger studies on HCV/HIV-co-infected individuals stratified by ethnicity and the inclusion of mRNA/protein expression of other genes associated with inflammation and fibrogenesis would shed light on these results. Further studies of genetic polymorphisms linked to ethnicity are also warranted to explain the differences in the expression of these PPARs. 

Funding source
This research was funded by Bristol-Myers Squibb through a grant within the Virology Fellows Research Training Program.

Table 2 - PPARα mRNA expression: univariate and multivariate linear regression analyses.

| Univariate analyses | Beta (95% CI); p-value | Multivariate Analysis | Beta (95% CI); p-value |
|---------------------|-----------------------|----------------------|-----------------------|
| HIV +               | -0.175 ((-0.057) - (-0.007)); 0.1 | -0.225 ((-0.064) - (-0.001)); p=0.06 |
| Age                 | -0.086((-0.003) - (-0.001)); 0.4 |                       |                       |
| Male sex            | -0.209((-0.067) - (-0.003)); 0.07 |                       |                       |
| BMI                 | 0.067 ((-0.003) - 0.005); 0.6 |                       |                       |
| Black race          | 0.272 (0.008 – 0.079); 0.02 | 0.225 (-0.008 - 0.080); 0.1 |                       |
| United States       | 0.333 (0.016 - 0.078); 0.003 | 0.197((-0.010) - 0.065); 0.1 |                       |
| HCV-1 genotype      | 0.216 ((-0.006) - (0.126)); 0.07 |                       |                       |
| HCV RNA             | -0.144 ((-0.000) - 0.000); 0.3 |                       |                       |
| METAVIR F3/F4       | -0.112((-0.068) - (0.024)); 0.3 |                       |                       |
| METAVIR A2/A3       | 0.063 ((-0.024) – (0.041)); 0.6 |                       |                       |
| Steatosis (yes vs. no) | -0.105 ((-0.057) – (0.024)); 0.4 |                       |                       |
| DM                  | 0.054 ((-0.04) – (0.063)); 0.6 |                       |                       |
| Alcohol use         | 0.120 ((-0.017) – (0.055)); 0.3 |                       |                       |
| CD4 counts          | -0.235 (0.000 - 0.000); 0.3 |                       |                       |
| HIV RNA levels      | 0.112 (0.000 - 0.000); 0.7 |                       |                       |
| HAART regimen       | 0.333 (0.001 - 0.005); 0.03 | 0.266 (0.000 - 0.005); 0.04 |                       |
| AZT                 | -0.337 ((-0.029) – (0.000)); 0.051 |                       |                       |
| Dideoxynucleosides  | 0.029 ((-0.090) – (0.016)); 0.9 |                       |                       |
| Pi                  | -0.038 ((-0.052) - 0.042); 0.8 |                       |                       |

BMI: body mass index; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes mellitus.

Table 3 - PPARγ mRNA expression: univariate and multivariate linear regression analyses.

| Univariate analyses | Beta (95% CI); p-value | Multivariate Analysis | Beta (95% CI); p-value |
|---------------------|-----------------------|----------------------|-----------------------|
| HIV +               | -0.330 ((-0.005) - (-0.001)); 0.004 | -0.392 ((-0.005) - (-0.001)); p=0.001 |
| Age                 | -0.142 (0.000 - 0.000); 0.2 |                       |                       |
| Male sex            | -0.046 ((-0.003) - (-0.002)); 0.7 |                       |                       |
| BMI                 | 0.085 (0.000 - 0.000); 0.9 |                       |                       |
| Black race          | 0.25 (0.000 – 0.005); 0.03 | 0.266 (0.000 - 0.005); 0.04 |                       |
| United States       | 0.333 (0.001 - 0.005); 0.003 | 0.166 ((-0.001) - 0.004); 0.2 |                       |
| HCV-1 genotype      | 0.133((-0.002) - (0.006)); 0.3 |                       |                       |
| HCV RNA             | -0.109 (0.000 - 0.000); 0.4 |                       |                       |
| METAVIR F3/F4       | -0.08 ((-0.004) – (0.002)); 0.5 |                       |                       |
| METAVIR A2/A3       | 0.128 ((-0.001) – (0.003)); 0.9 |                       |                       |
| Steatosis (yes vs. no) | -0.051 ((-0.003) – (0.002)); 0.7 |                       |                       |
| Diabetes            | 0.056 ((-0.002) – (0.004)); 0.6 |                       |                       |
| Alcohol use         | 0.065 ((-0.002) – (0.003)); 0.5 |                       |                       |
| CD4 counts          | -0.07 (0.000 - 0.000); 0.7 |                       |                       |
| HIV RNA levels      | -0.017 (0.000 - 0.000); 0.9 |                       |                       |
| HAART regimen       | 0.333 (0.001 - 0.005); 0.03 | 0.266 (0.000 - 0.005); 0.04 |                       |
| AZT                 | -0.297 ((-0.005) – (0.000)); 0.09 |                       |                       |
| Dideoxynucleosides  | -0.022 ((-0.006) – (-0.005)); 0.9 |                       |                       |
| Pi                  | -0.06 ((-0.003) - 0.002); 0.7 |                       |                       |

BMI: body mass index; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes mellitus.
AUTHOR CONTRIBUTIONS
Nunez M and High K conceived and designed the study. Shores N, Mendes-Correa MC, Maida I, Turner J and Babudieri S were responsible for the data acquisition. Nunez M, Shores N, High K, Turner J, Mendes-Correa MC and Maida I were responsible for the data analysis and interpretation. Nunez M, Shores N and Turner J were responsible for the manuscript drafting. Nunez M was responsible for the statistical analysis. Turner J was responsible for the technical and material support. Nunez M supervised the study. All authors have accepted the content of the manuscript.

REFERENCES
1. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138(3):197-207, http://dx.doi.org/10.7326/0003-4819-138-3-200302040-00012.
2. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53(3):1023-34, http://dx.doi.org/10.1002/hep.24148.
3. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy M, Podevin P, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128(2):334-42, http://dx.doi.org/10.1053/j.gastro.2004.11.016.
4. De Gottardi A, Piazzini V, Pagnelle P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, et al. Peroxisome proliferator-activated receptor alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther. 2006;23(1):107-14, http://dx.doi.org/10.1111/j.1365-2036.2006.02729.x.
5. Yang L, Chan C, Kwon O, Liu S, McGhee J, Stimpson SA, Chen LZ, et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2006;291(5):G902-11, http://dx.doi.org/10.1152/ajpgi.00124.2006.
6. Le monde M, Barbou V, Girard P, Kim M, Bastard JP, Wendum D, Paye F, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected subjects. AIDS. 2006;20(3):387-95, http://dx.doi.org/10.1097/01.aids.0000205033.01356.11.
7. Blackard JT, Sherman KE. HIV/HCV co-infection: time to reevaluate the role of HIV in the liver? J Viral Hepat. 2008;15(5):323-30, http://dx.doi.org/10.1111/j.1365-2893.2008.00970.x.
8. Lonardo A, Adinolfi LE, Restivo I, Ballestri S, Romagnoli D, Baldelli E, Nasimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 2014;20(23):7089-103, http://dx.doi.org/10.3748/wjg.v20.23.7089.
9. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hoiby HN. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95, http://dx.doi.org/10.1002/hep.20466.
10. Machado MV, Cortez-Pinto H. Nuclear receptors: do they position in non-alcoholic fatty liver disease treatment? Liver Int. 2014;34(9):1291-4, http://dx.doi.org/10.1111/liv.12578.
11. Yasui K, Harazono Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, et al. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese subjects infected with hepatitis C virus. J Gastroenterol. 2010;45(1):95-104, http://dx.doi.org/10.1002/jgastro.200901133-8.
12. Wu C, Gilroy R, Taylor R, Olyaei M, Abdulkarim B, Forster J, O'Neill M, et al. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatic C virus subjects with and without a history of alcohol drinking. Hepatology. 2011;54(6):1966-74, http://dx.doi.org/10.1002/hep.24645.
13. Karpen S. Nuclear receptor regulation of hepatic function. J Hepatol. 2002;36(6):832-50, http://dx.doi.org/10.1016/S0168-8278(02)00129-0.
14. Marra F, Isele E, Romanelli RG, Caligiuri A, Pastacalci S, Batignani G, Bonacchi A, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119(2):466-78, http://dx.doi.org/10.1053/gast.2000.9365.
15. Goodman BD, Becker RL, Pockros PJ, Adhikari NJ. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007;45(4):886-94, http://dx.doi.org/10.1002/hep.21595.
16. Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology. 2006;130(7):795-814, http://dx.doi.org/10.1053/j.gastro.2009.06.040.
17. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mesrobian A, Chen P, et al. Human immunodeficiency virus (HIV-1) infects human hepatic stellate cells and promotes collagen I and monocyte chemotactic protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology. 2010;52(2):612-22, http://dx.doi.org/10.1002/hep.23679.